Table 6. Adverse events.
AZI-M/CT, azilsartan-medoxomil/chlorthalidone; OLM/HCTZ, olmesartan-medoxomil/hydrochlorothiazide; n, number of patients
| Study and year | Hypotension (n) | Dizziness (n) | Headache (n) | Diarrhea (n) | Fatigue (n) | Myocardial infraction (n) | Cardiac arrest (n) | Pharyngitis (n) | ||||||||
| AZI- M/C T | OL M/H CTZ | AZI- M/CT | OLM/ HCTZ | AZI- M/CT | OLM/ HCTZ | AZI- M/CT | OLM/H CTZ | AZI- M/CT | OLM/H CTZ | AZI- M/CT | OLM/ HCTZ | AZI- M/CT | OLM/ HCTZ | AZI- M/CT | OLM/ HCTZ | |
| Cushmann et al. (2012) [5] | - | -- | 99 | 29 | 32 | 26 | - | - | 47 | 16 | - | - | - | - | - | - |
| Neutel et al. (2017)[11] | - | - | 68 | 53 | 31 | 46 | - | - | 21 | 17 | 0 | 1 | 1 | 0 | - | - |
| Cushmann et al. (2018)[12] | 7 | 1 | 49 | 20 | 28 | 18 | 27 | 5 | 21 | 5 | - | - | - | - | - | - |
| Bakris et al. (2018)[13] | 4 | 3 | 6 | 5 | 8 | 2 | 1 | 4 | 3 | 4 | - | - | - | - | 0 | 4 |